Organon (OGN) Laps the Stock Market: Here's Why
The latest trading day saw Organon (OGN) settling at $9.05, representing a +1.23% change from its previous close.
Organon (OGN) Earnings Expected to Grow: Should You Buy?
Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Organon (OGN) closed at $9.28, marking a -1.07% move from the previous day.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You Trade
Organon (OGN) reached $10.84 at the closing of the latest trading day, reflecting a -1.54% change compared to its last close.
Organon (OGN) Outperforms Broader Market: What You Need to Know
Organon (OGN) reached $10.35 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
OGN vs. HQY: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)
Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Kevin Ali - CEO & Director Matthew M. Walsh - Executive VP & CFO Conference Call Participants Alexandra Doering von Riesemann - Piper Sandler & Co., Research Division Ethan Harris Brown - JPMorgan Chase & Co, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.
